


PRODUCT INFORMATION



Cyclic GMP (sodium salt)

Item No. 18821

CAS Registry No.: 40732-48-7
Formal Name: cyclic 3',5'-(hydrogen phosphate)
guanosine, monosodium salt
Synonyms: cGMP, Cyclic guanosine monophosphate,
Guanosine 3'5'-cyclic monophosphate,
Monosodium-GMP
MF: C₁₀H₁₁N₅O₇P • Na
FW: 367.2
Purity: ≥98%
UV/Vis.: λ_{max}: 256 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cyclic GMP (cGMP) (sodium salt) is supplied as a crystalline solid. cGMP (sodium salt) is slightly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

cGMP is a second messenger that is biosynthesized from GTP by guanylate cyclases. Activators of guanylate cyclases include nitric oxide and natriuretic peptides.¹ cGMP activates protein kinase G (PKG) and modulates ion channel conductance, with signaling affecting diverse processes including smooth muscle relaxation and proliferation, phototransduction, and energy homeostasis.¹⁻⁴ The degradation of cGMP to GMP is mediated by specific and non-specific phosphodiesterases.^{5,6}

References

1. Hamad, A.M., Clayton, A., Islam, B., *et al.* Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. *Am. J. Physiol. Lung Cell Mol. Physiol.* **285**(5), L973-L983 (2003).
2. Tulis, D.A. Novel therapies for cyclic GMP control of vascular smooth muscle growth. *Am. J. Ther.* **15**(6), 551-564 (2008).
3. Koch, K.-W. and Dell'Orco, D. Protein and Signaling Networks in Vertebrate Photoreceptor Cells. *Front. Mol. Neurosci.* **8**(67), (2015).
4. Kim, G.W., Lin, J.E., Blomain, E.S., *et al.* Antiobesity pharmacotherapy: New drugs and emerging targets. *Clin. Pharmacol. Ther.* **95**(1), 53-66 (2014).
5. DeNinno, M.P. Future directions in phosphodiesterase drug discovery. *Bioorg. Med. Chem. Lett.* **22**(22), 6794-6800 (2012).
6. Rotella, D.P. Phosphodiesterase 5 inhibitors: Current status and potential applications. *Nat. Rev. Drug Discov.* **1**(9), 674-682 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/03/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM